Trial results

Exenatide for Smoking Cessation and Prevention of Weight Gain

NCT05610800 on ClinicalTrials.gov · last registry update 2026-03-23

Finished 7 November 2025, after enrolling 140 people. exenatide is approved in the US, but not for obesity and substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

COMPLETED

Phase

P2

Drug

exenatide

Byetta, Bydureon

Sponsor

The University of Texas Health Science Center, Houston

Sponsor type

Other

Enrollment

140

Started

2022-12-07

Primary completion

2025-11-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage of participants with 4-week continuous abstinence at 12 weeks post-target quit day as assessed by self-report timeline followback (TLFB) and verified by breath carbon monoxide (CO) level

Conditions studied

Smoking Cessation · Weight Gain

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.